Cerca Biotech highlights MammaTyper LRP study at ECP 2026

Cerca Biotech says investigators presented SCORE study results at the 2026 European Congress of Pathology showing the MammaTyper Low-Risk Prediction model may help identify HR+/HER2− breast cancer patients with Oncotype DX recurrence scores of 25 or lower. The company says the assay could offer a local, lower-cost pre-screen to help guide chemotherapy decisions.

Why it matters: - Cerca Biotech is positioning MammaTyper® LRP as a local, lower-cost way to pre-screen HR+/HER2− breast cancer patients who are unlikely to benefit from chemotherapy. - The model is aimed at identifying patients with an Oncotype DX® Recurrence Score of 25 or lower, a group commonly considered lower risk. - A high-performing pre-screen could reduce the need for more expensive send-out testing and speed treatment planning in some settings.

What happened: - Investigators presented SCORE study findings at the 2026 European Congress of Pathology in Berlin. - The multicenter retrospective study evaluated 211 archived breast cancer tissue samples from patients who already had Oncotype DX® Recurrence Score results. - The study team included investigators from Vall d'Hebron University Hospital, Virgen de la Victoria University Hospital, and Malaga Biomedical Research Institute in Spain.

The details: - MammaTyper® LRP is calculated from ESR1, PGR and MKI67 mRNA expression. - The model identified patients classified as low recurrence risk by Oncotype DX® with a positive predictive value of 95%. - The study focused on HR+/HER2− breast cancer. - Cerca Biotech linked the presentation to a pre-screening use case for patients with Oncotype DX® RS ≤25. - The press release says the findings confirm previously presented results from a multicenter German study led by H-A Lehr and colleagues in 2019. - The release also says the results align with a 2026 Chinese retrospective study showing the MammaTyper® LRP score was an independent prognostic factor in early-stage HR+/HER2− breast cancer and that LRP low-risk patients did not benefit from adjuvant chemotherapy. - Rich Hughes, Cerca Biotech’s commercial director, said the findings support MammaTyper® LRP as a locally available low-cost molecular pre-screen and said the company is encouraged by the SCORE results.

Between the lines: - The presentation reinforces a broader push for locally available tests that can triage patients before more expensive genomic assays are used. - The combination of retrospective validation, high positive predictive value and consistency with prior studies strengthens the case for additional prospective evaluation. - The company is also trying to expand the value proposition for MammaTyper® beyond tumor subtyping into treatment-decision support.

What's next: - Cerca Biotech is promoting MammaTyper® as a potentially widely accessible molecular tool for personalized breast cancer treatment. - Further validation would likely be needed before the LRP model could be adopted broadly as a clinical pre-screen. - More information about MammaTyper® is available here. - The ECP 2026 presentation is listed in the congress programme.

The bottom line: - Cerca Biotech says the SCORE study adds to evidence that MammaTyper® LRP may help identify lower-risk HR+/HER2− breast cancer patients more cheaply and locally than current multigene testing pathways.